Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29480716 | 0.83 | CHRNB2 (0.33) | KMT2ATHRBCHRNB2CHRNA4DGAT1 | |
| SCHEMBL22735755 | 0.83 | CHRNB2 (0.33) | KMT2ATHRBCHRNB2CHRNA4DGAT1 | |
| SCHEMBL67213 | 0.82 | KMT2A (0.47) | KMT2ATHRBL3MBTL1TRPV1TSHR | |
| SCHEMBL13010773 | 0.82 | TSHR (0.39) | CHRNB2CHRNA4DGAT1L3MBTL1HDAC1 | |
| SCHEMBL29480714 | 0.80 | GCK (0.46) | — | |
| SCHEMBL5199624 | 0.80 | GCK (0.46) | — | |
| SCHEMBL28017609 | 0.78 | L3MBTL1 (0.33) | KMT2ATHRBCHRNB2CHRNA4L3MBTL1 | |
| SCHEMBL24129962 | 0.78 | PDE2A (0.38) | KMT2ACHRNB2CHRNA4DGAT1PDE2A | |
| SCHEMBL746530 | 0.78 | TNKS (0.37) | KMT2ACHRNB2CHRNA4 | |
| SCHEMBL30043054 | 0.78 | TNKS (0.37) | KMT2ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568960-B1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20250236614-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4568960-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| CN-119677733-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-115667257-B | Compounds for inhibiting CDK7 | 伊莱利利公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024033458-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-02-15 | — | — | WO | disclosed |
| US-9994591-B2 | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-12 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | BOEHRINGER INGELHEIM INERNATIONAL GMBH (DE) | 2018-02-08 | — | — | US | disclosed |
| WO-2018024653-A1 | OXADIAZOLOPYRIDINE DERIVATES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018024653-A1 | OXADIAZOLOPYRIDINE DERIVATES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-08 | — | — | WO | disclosed |
| EP-2929883-A1 | Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors | INSTITUT PASTEUR (FR) | 2015-10-14 | — | — | EP | disclosed |
| EP-2488030-B1 | 1-(PYRID-3-YL)-PYRAZOLES AND 1-(PYRIMID-5-YL)-PYRAZOLES AS PEST CONTROLLERS | BAYER CROPSCIENCE AG (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2488030-A1 | 1- (PYRID-3-YL) -PYRAZOLE AND 1- (PYRIMID-5-YL) -PYRAZOLE AS PESTICIDE | Bayer CropScience AG (DE) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045224-A1 | 1- (PYRID-3-YL) -PYRAZOLE AND 1- (PYRIMID-5-YL) -PYRAZOLE AS PESTICIDE | BAYER CROPSCIENCE AG (DE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037594-A1 | Oxadiazolopyridine Derivates for Use as Ghrelin O-Acyl Transferase (GOAT) Inhibitors | MBOAT4, GIPR, ACAT1 | MBOAT4 1/4885KMT2A 2700/4885THRB 168/4885 |
| US-20250236614-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES | GRIN2C, CNR1, CNR2 | MBOAT4 3241/4885KMT2A 440/4885THRB 943/4885 |
| US-12258328-B2 | 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | MBOAT4 4802/4885KMT2A 1963/4885THRB 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.